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demonstrated continuous flow synthesis of the API uses 
dihydroartemisinic acid (DHAA), a waste component 
of the currently implemented batch separation, as 
a feedstock (26, 28). Toluene is the carrier solvent 
for the process (Figure 1). The demonstrated batch 
separation comprises 17 stages (including neutralisation, 
evaporation, drying, washes, crystallisations and 
filtrations) to obtain the API at 70.1% yield (26). Here, 
we consider continuous antisolvent crystallisation of 
artemisinin (similar to recent efforts for artemisinin 
crystallisation (29)), comparing ethyl acetate (EtOAc) 
and acetonitrile (ACN) as candidate antisolvents (Figure 
2). S:F ratios of 2.33 and 4 are considered for EtOAc 
and ACN, respectively. In both cases, the feed to the 
continuous crystalliser is considered at 90% API saturation 
in the toluene-antisolvent mixture at 40 °C, and the 
target mother liquor composition is the API saturation 
concentration of the mixture at 5 °C. A flash evaporation 
for solvent removal is required to meet the desired feed 
composition. The API recovery is calculated as the 
thermodynamically possible crystallisation yield from 
these respective conditions.
ATTAINABLE RECOVERIES AND MATERIAL EFFICIENCIES 
API recoveries and material efficiencies for batch and 
continuous separations are compared. Material efficiences 
are quantified by the environmental (E)-factor, the mass 
ratio of waste-to-product, and the mass productivity (MP), 
quantifying how efficiently material is used (12). Continuous 
separations are modelled as single-stage ideal processes. 
Efficiencies versus thermodynamic equilibrium (80, 90 and 
100%) are considered to account for continuous stage 
inefficiencies.
API Recoveries 
The continuous LLE of diphenhydramine attains API 
recoveries of 70.6−88.3% for CyHex and 64.9−81.1% for 
MeCyHex (Figure 3). Improved recoveries relative to the 
batch separation (25) are only attainable when 100% 
efficiency versus thermodynamic equilibria is assumed. This 
highlights the importance of considering stage efficiencies of 
continuous separation processes. 
Here, we present and discuss the steady-state process 
modelling results of the CPM for two APIs, diphenhydramine 
(this work) and artemisinin (17), whose conceptual 
continuous separations show improvements over the batch 
methods. API recoveries and material efficiencies are 
compared for batch and continuous separation options. 
In both cases, a plant capacity of 100 kg API per annum 
and 8000 h of annual operation are assumed. Figure 1 
shows conceptual flowsheets and demonstrated reaction 
pathways for the CPM of both APIs. Both APIs are produced 
in flow using plug flow reactors (PFRs), in accordance with 
experimental studies (24).
Diphenhydramine 
Diphenhydramine is most commonly used as a first-
generation antihistamine and is globally marketed in various 
brand formulations (Benadryl®, Unisom®, Tylenol®, Zzzquil®). 
The continuous flow synthesis of diphenhydramine (25) 
features a single-step synthesis at 180 °C (Figure 1) between 
chlorodiphenylmethane (CDPM) and dimethylaminoethanol 
(DMAE) in carrier solvent, N-methylpyrrolidone (NMP).  
The demonstrated batch separation of diphenhydramine 
employs a three-stage liquid-liquid extraction (LLE) with 
diethyl ether, attaining an API recovery of 80% (25). 
We compare a single-stage continuous LLE separation 
(Figure 2) to the batch separation. Cyclohexane (CyHex) 
and methylcyclohexane (MeCyHex) are compared 
as continuous LLE solvents, considering an operating 
temperature of 20 °C and a solvent-to-feed ratio (S:F, mass 
basis) of 5.
Modelling of continuous LLE of diphenhydramine requires 
estimation of the composition of each liquid phase in the 
process and of the API solubility in each phase. Liquid-liquid 
and solid-liquid equilibria are estimated via the UNIFAC and 
NRTL models. The partition coefficient of API between liquid 
phases is assumed to equal the ratio of API solubilities in 
each phase.
Artemisinin 
Artemisinin is traditionally produced by extensive 
batch cultivation and extraction (27). A recently 
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Abstract The pharmaceutical industry is currently dominated by the traditionally implemented, yet wasteful and inefficient, batch production paradigm. Continuous Pharmaceutical Manufacturing (CPM) shows 
potential to bring technological innovation, cost savings and environmental benefits to pharmaceutical production. This paper 
describes the process modelling and simulation of CPM of two active pharmaceutical ingredients (APIs): diphenhydramine (a 
globally-marketed antishistamine) and artemisinin (an important antimalarial drug), with focus on implementing a continuous 
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are compared to the batch methods, in order to demonstrate the benefits of material efficiency and economic viability of continuous 
separations in pharmaceutical manufacturing. 
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INTRODUCTION
Batch manufacturing methods have historically dominated 
the pharmaceutical industry, with benefits of versatile 
equipment usage, specific batch recall, long residence 
times for exploring different reaction pathways (1), and 
well-established regulatory protocol (2). However, batch 
manufacturing necessitates large equipment, intensive labour 
(3), limited automation and frequent plant reconfiguration 
(4). Additionally, costs associated with R&D and bringing 
new drug products to market have drastically increased 
over previous decades (5). Increasing competition from 
generics manufacturers also poses a significant threat to 
pharmaceutical firm profitability. Technological innovation 
is required to ensure sustainability for pharmaceutical 
enterprises (6).
Continuous Pharmaceutical Manufacturing (CPM) is a 
new production paradigm receiving attention from the 
highest regulatory levels due to its potential for reduced 
costs, lower material requirements and waste handling and 
smaller footprints (7). CPM offers enhanced mixing and 
heat transfer efficiencies, safer operation under hazardous 
conditions and improved yields (8). However, CPM is yet to 
be widely adopted due to significant investments in batch 
infrastructures (2) and legislative constraints (9). Furthermore, 
challenges in scaleup and solids handling are critical issues 
to be addressed (10). To facilitate the transition from batch 
manufacturing, CPM benefits must be conclusively illustrated 
for active substances of societal importance and high global 
demand (11).
Pharmaceutical manufacturing is one of the most wasteful 
industrial sectors, producing 200 times more waste than 
petroleum manufacturing (12). Approximately 56% of this 
waste is attributed to solvent usage (13). Separations in 
upstream pharmaceutical manufacturing are particularly 
wasteful due to strict product purity requirements (14). To 
elucidate CPM waste reduction and economic benefits, 
continuous separation process alternatives must be 
investigated.
Candidate separation process screening via process 
modelling and simulation is critical prior to financial 
investments in experimentation and scaleup (15-16) as 
detailed in recent studies (11, 17-18). This work demonstrates 
the benefits of continuous separations by examining two 
API case studies: diphenhydramine (this work), a popular 
antihistamine, and artemisinin (17), an important antimalarial 
drug. Theoretical modelling of conceptual continuous 
separations illustrates the importance of conducting 
technoeconomic analyses in the early stages of design to 
identify promising candidate CPM processes.
GREEN CONTINUOUS FLOW SYNTHESES AND SEPARATIONS 
To demonstrate the feasibility and viability of continuous 
separations in pharmaceutical manufacturing, promising 
unit operations must be investigated for integration into fully 
continuous (CPM) flowsheets. Continuous flow syntheses of 
a wide range of APIs and the development of continuous 
downstream processes is documented in the literature (19-23). 
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Figure 1. Conceptual flowsheets for continuous production of A. 
Diphenhydramine, adapted from Snead and Jamison, 2013 (25), B. 
Artemisinin (17), adapted from Kopetzki et al., 2013 (26).
Figure 2. Continuous separation: A. Diphenhydramine (liquid-liquid 
extraction), B. Artemisinin (crystallisation) (17).
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ACN usage leads to an OpEx increase of 25.5−56.2%. This 
difference is due to the poorer API recovery and high S:F required 
for ACN compared to EtOAc. Total costs savings of 5.8−22.5% 
are attainable using EtOAc. For ACN, total costs savings of 
6.5 % and 14.5% are attainable (for 90 and 100% efficiencies 
versus thermodynamic equilibrium, respectively), whilst an 
increase in total costs of 3.3% is incurred for 80% efficiency versus 
thermodynamic equilibrium. EtOAc usage allows greater total 
costs savings for all efficiencies considered; thus, its usage for 
continuous crystallisation of artemisinin is preferred.
The present technoeconomic analysis of both CPM processes 
indicates that continuous separation allows for significant material 
efficiency and cost savings over batch separation methods. 
Process modelling for plantwide simulation and economic 
analysis employ essential assumptions, and the scaling up of CPM 
processes can induce cost saving variations, as we have already 
demonstrated (18). Life-Cycle Analysis (LCA) investigations of 
plant operation and capacity effects are thus encouraged. 
CONCLUSIONS
Continuous Pharmaceutical Manufacturing (CPM) has 
been established as a promising alternative to the currently 
implemented batch methods in the pharmaceutical industry. 
Process modelling and simulation facilitates the screening 
of candidate unit operations for purification of active 
pharmaceutical ingredients (APIs). The CPM case studies 
described here for two critical APIs, diphenhydramine and 
artemisinin (17), demonstrate the benefits of enhanced 
material efficiency and cost savings attainable via continuous 
separation and the importance of separation solvent selection. 
A more detailed technoeconomic analysis which highlights 
methodological background details has also been published 
(34). Systematic process modelling and simulation approaches 
facilitate the quantification of enhanced process performance 
and the design of efficient, cost-effective separations, towards 
meaningful transitions to continuous manufacturing in the 
pharmaceutical industry.
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ECONOMIC BENEFITS OF CONTINUOUS SEPARATIONS
Demonstrating the cost savings benefits available via CPM is 
imperative in order to make a convincing business case. Our 
economic analysis compares the cost benefits available by 
implementing continuous separations. Capital (CapEx) and 
operating (OpEx) expenditures and total costs (adjusted for 
inflation) for a 20-year lifetime and a 5% discount rate have 
been calculated. The designed CPM plants are considered 
at an existing pharmaceutical manufacturing site, with 
essential auxiliary infrastructure available. Plant throughputs 
and unit size modelling consider reported reaction and 
projected separation efficiencies to meet the required plant 
capacity. Calculation of CapEx, OpEx and total costs follow 
the methodology of a published CPM economic analysis (32). 
CapEx comprises battery limits installed costs and working 
capital and construction. OpEx comprises materials, utilities 
and waste handling requirements. Equipment and material 
prices are quoted from various vendors. Equipment costs 
have been scaled for varying unit sizes and year of purchase. 
Cost savings of continuous separation options relative to the 
batch separations are shown in Figure 4.
Continuous LLE of diphenhydramine allows significant CapEx 
savings: 28.5−36.3% savings are available using CyHex, and 
25.6−34.0% savings are available using MeCyHex (Figure 
4). Such cost savings are attainable due to the reduced 
equipment sizes via CPM (33). Using 
CyHex leads to 47.6−84.5% increase 
in OpEx due to the large solvent 
quantity (S:F = 5) required to meet 
the calculated API recovery and the 
high price of CyHex. Meanwhile, OpEx 
savings of 35.2−48.1% using MeCyHex 
are available, due to the lower material 
price compared to CyHex. The total 
costs savings benefits of implementing 
MeCyHex (27.9−37.4%) are significantly 
greater than for CyHex (1.7−16.4%). 
MeCyHex is the best candidate LLE 
solvent for CPM of diphenhydramine 
based upon the economics presented.
For the continuous crystallisation of 
artemisinin, CapEx savings of 6.6−22.4% 
are available for EtOAc usage. A 
slight increase in CapEx (0.3%) is 
incurred when assuming 80% efficiency 
versus thermodynamic equilibrium 
for ACN usage; CapEx savings of 
9.2% and 16.9% are attainable when 
considering 90% and 100% efficiencies 
versus thermodynamic equilibrium, 
respectively. Such savings are mainly 
due to the significant reduction in 
equipment requirements for the 
continuous separation in comparison 
to the 17-step batch route (26). 
OpEx savings of 4.4% and 22.5% are 
attainable using EtOAc (for 90 and 
100% efficiencies versus thermodynamic 
equilibrium, respectively), whilst an 
OpEx increase of 7.3% is incurred for 
80% efficiency versus thermodynamic 
equilibrium.  
For the continuous crystallisation of artemisinin from the 
toluene-antisolvent mixture, EtOAc attains higher API 
recoveries (45.8−57.2%) than ACN (42.1−52.6%) as shown in 
Figure 3. The batch separation system attains an API recovery 
of 70.1% due to its extensive nature (26). EtOAc is the most 
promising antisolvent for CPM, attaining higher API recoveries 
compared to ACN (Figure 3). A broader antisolvent 
consideration must also include safety, ecotoxicity and life 
cycle assessment (31). Process Analytical Technology (PAT), 
high-fidelity instrumentation and (preferably model-based) 
automatic control strategies (28) are essential to ensure the 
intended continuity of the process, and the minimisation of 
inevitable start-up and shut-down times.
Material Efficiencies: E-Factors and Mass Productivities 
The continuous LLE of diphenhydramine incurs poorer material 
efficiencies (higher E-factors, lower MPs) than the batch 
separation for both LLE solvents (Table 1) due to the large 
volumes of LLE solvent required to attain comparable API 
recoveries. Nevertheless, computed E-factors and MPs are still 
acceptably low for pharmaceutical processes (30).
The continuous crystallisation of artemisinin is significantly more 
efficient is terms of material usage than the batch separation 
(26), as shown in Table 1. This is due to the greater number 
of unit operations and material requirements for the batch 
separation (26) compared to our conceptual continuous 
separation process (17-18). 
Figure 3. Comparison of the performances of continuous separation schemes vs. batch separation methods (17).
Table 1. Environmental (E)-factors and mass productivities (MPs).
Figure 4. A comparative illustration of CapEx, OpEx and Total Cost of continuous separations (18).
